Optimi Health Corp. (TSE:OPTI) has released an update.
Optimi Health Corp., a leader in the psychedelics pharmaceutical industry, has successfully completed the in-house production and third-party validation of three batches of MDMA Active Pharmaceutical Ingredient (API), marking a significant quality and manufacturing milestone. This advancement highlights Optimi’s ability to fulfill international supply agreements, as evidenced by their recent deal with the Institute for Psychedelic Research at Tel Aviv University. The company emphasized its competitive advantage in the market, underlined by cost savings from its in-house production capabilities.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
